• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC | Inspections

New Search Back to Search Results
Note: this medical device has supplements. The device description may have changed. Be sure to look at the supplements to get an up-to-date view of this device.
Classification Nameassay,hybridization and/or nucleic acid amplification for detection of hepatitis c rna,hepatitis c virus
PMA NumberP060030
Date Received10/27/2006
Decision Date10/30/2008
Product Code
MZP[ Registered Establishments with MZP ]
Docket Number 09M-0033
Notice Date 01/27/2009
Advisory Committee Microbiology
Expedited Review Granted? No
Combination Product No
Information About: Labeling, Approval Order, Summary of Safety and Effectiveness
Recalls CDRH Recalls
Approval Order Statement 
Approval for the cobas ampliprep/cobas taqman hcv test. This device is an in vitro nucleic acid amplification lest for the quantitation of hepatitis c viral (hcv) rna in human plasma or serum of hcv-infected individuals using the cobas ampliprep instrument for automated specimen processing and the cobas taqman analyzer or the cobas taqman 48 analyzer for automated amplification and detection. Specimens containing hcv genotypes 1 - 6 have been validated for quantitation in the assay. The cobas ampliprep/cobas taqman hcv test is intended for use as an aid in the management of hcv-infected individuals undergoing anti-viral therapy. The assay measures hcv rna levels at baseline and during treatment and can be utilized to predict sustained and non-sustained virological response to hcv therapy. The results from the cobas ampiprep/cobas taqman hcv test must be interpreted within the context of all relevant clinical and laboratory findings. Assay performance characteristics have been established for individuals treated with peginterferon alfa-2a plus ribavirin. No information is available on the assay's predictive value when other therapies are used. Assay performance for determining the slate of hcv infection has not been established. ".
Approval Order Approval Order
Supplements: S001 S002 S003 S004 S005 S006 S007 S008 S009 
S010 S012 S014 S015 S016 S017 S018 S020 S021 
S022 S023 S024 S025 S026 S027 S028 S029 S030 
S031 S032 S033 S034 S035 S036 S037 S038 S039 
S040 S041 S042 S043 S044 S045 S046 S047